RNA interference (RNAi) is a novel concept to target transcripts derived from HBV covalently closed circular DNA. The study by Wooddell et al. investigates the RNAi-based therapy ARC-520 in patients and chimpanzees with chronic HBV infection and uncovers HBV DNA integration as a crucial source of hepatitis B surface antigen, which has not been considered in current strategies to accomplish HBV cure.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370–398 (2017).
Bock, C. T. et al. Structural organization of the hepatitis B virus minichromosome. J. Mol. Biol. 307, 183–196 (2001).
Seeger, C. & Mason, W. S. Molecular biology of hepatitis B virus infection. Virology 479–480, 672–686 (2015).
Cornberg, M. et al. The role of quantitative hepatitis B surface antigen revisited. J. Hepatol. 66, 398–411 (2017).
Testoni, B., Durantel, D. & Zoulim, F. Novel targets for hepatitis B virus therapy. Liver Int. 37 (Suppl. 1), 33–39 (2017).
Bertoletti, A. & Ferrari, C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61, 1754–1764 (2012).
Wooddell, C. I. et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci. Transl Med. 9, eaan0241 (2017).
Höner zu Siederdissen, C., Maasoumy, B. & Cornberg, M. What is new on HBsAg and other diagnostic markers in HBV infection. Best Pract. Res. Clin. Gastroenterol. 31, 281–289 (2017).
Allweiss, L. et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut https://doi.org/10.1136/gutjnl-2016-312162 (2017).
Bogomolov, P. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J. Hepatol. 65, 490–498 (2016).
Acknowledgements
The authors thank F. Rinker for drafting the figure and T. Bock for critical review of the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
M.C. received payments for lectures and consultation from Bristol-Myers Squibb, Gilead Sciences and Roche. M.M. received payments for lectures, consultation and trial support from Bristol-Myers Squibb, CureVac, Gilead Sciences, Glaxo Smith Kline, MSD, Novartis and Roche.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Cornberg, M., Manns, M. No cure for hepatitis B and D without targeting integrated viral DNA?. Nat Rev Gastroenterol Hepatol 15, 195–196 (2018). https://doi.org/10.1038/nrgastro.2017.185
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.185
This article is cited by
-
Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV
Current Hepatology Reports (2019)
-
Role of HBsAg Testing in the Management of Patients with Chronic HBV
Current Hepatology Reports (2019)
-
Chronische Hepatitis B und D (delta)
Der Internist (2018)